Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients.

OBJECTIVE To evaluate the changing impact of genetic and clinicopathologic factors on conditional overall survival (CS) over time in patients with resectable colorectal liver metastasis. BACKGROUND CS estimates account for the changing likelihood of survival over time and may reveal the changing impact of prognostic factors as time accrues from the date of surgery. METHODS CS analysis was performed in 1099 patients of an international, multi-institutional cohort. Three-year CS (CS3) estimates at the "xth" year after surgery were calculated as follows: CS3 = CS (x + 3)/CS (x). The standardized difference (d) between CS3 rates was used to estimate the changing prognostic power of selected variables over time. A d < 0.1 indicated very small differences between groups, 0.1 ≤ d < 0.3 indicated small differences, 0.3 ≤ d < 0.5 indicated moderate differences, and d ≥ 0.5 indicated strong differences. RESULTS According to OS estimates calculated at the time of surgery, the presence of BRAF and KRAS mutations, R1 margin status, resected extrahepatic disease, patient age, primary tumor lymph node metastasis, tumor number, and carcinoembryonic antigen levels independently predicted worse survival. However, when temporal changes in the prognostic impact of these variables were considered using CS3 estimates, BRAF mutation dominated prognosis during the first year (d = 0.48), whereas surgeon-related variables (ie, surgical margin and resected extrahepatic disease) determined prognosis thereafter (d ≥ 0.5). Traditional clinicopathologic factors affected survival constantly, but only to a moderate degree (0.3 ≤ d < 0.5). CONCLUSIONS The impact of genetic, surgery-related, and clinicopathologic factors on OS and CS3 changed dramatically over time. Specifically, BRAF mutation status dominated prognosis in the first year, whereas positive surgical margins and resected extrahepatic disease determined prognosis thereafter.

[1]  M. Nichelatti,et al.  Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta‐Analysis , 2017, Clinical colorectal cancer.

[2]  Daniel J Sargent,et al.  Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Shannon,et al.  Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Yuhree Kim,et al.  Curative Surgical Resection of Adrenocortical Carcinoma: Determining Long-term Outcome Based on Conditional Disease-free Probability , 2017, Annals of surgery.

[5]  T. Pawlik,et al.  From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis. , 2016, Surgical oncology.

[6]  Yuhree Kim,et al.  Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases , 2016, Cancer.

[7]  T. Pawlik,et al.  Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases. , 2016, Anticancer research.

[8]  Yuhree Kim,et al.  Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. , 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[9]  A. Russo,et al.  Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. , 2016, Critical reviews in oncology/hematology.

[10]  J. Saric,et al.  Significance of R1 Resection for Advanced Colorectal Liver Metastases in the Era of Modern Effective Chemotherapy , 2016, World Journal of Surgery.

[11]  M. Gönen,et al.  Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection , 2016, Annals of surgery.

[12]  J. Vauthey,et al.  RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases , 2016, Journal of Gastrointestinal Surgery.

[13]  M. Barone,et al.  Conditional survival analysis of hepatocellular carcinoma patients treated with radiofrequency ablation , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  M. Choti,et al.  Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. , 2015, JAMA surgery.

[15]  A. Ejaz,et al.  Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 535 Patients. , 2015, JAMA surgery.

[16]  M. Choti,et al.  Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. , 2015 .

[17]  J. Weissfeld,et al.  Prognosis and conditional disease-free survival among patients with ovarian cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Hodson,et al.  Performance of prognostic scores in predicting long‐term outcome following resection of colorectal liver metastases , 2014, The British journal of surgery.

[19]  P. Balladur,et al.  Prognostic Impact of Positive Surgical Margins After Resection of Colorectal Cancer Liver Metastases: Reappraisal in the Era of Modern Chemotherapy , 2013, World Journal of Surgery.

[20]  R. Charnley,et al.  Prognostic Factors and Survival after Resection of Colorectal Liver Metastasis in the Era of Preoperative Chemotherapy: An 11-Year Single-Centre Study , 2013, Digestive Surgery.

[21]  J. Shindoh,et al.  Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases , 2012, Annals of surgery.

[22]  L. Bolondi,et al.  Conditional Survival after Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients , 2012, Clinical Cancer Research.

[23]  M. Choti,et al.  Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent , 2012, Cancer.

[24]  Hermann Brenner,et al.  Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Meyerhardt,et al.  Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.

[26]  R. Adam,et al.  R1 Resection by Necessity for Colorectal Liver Metastases: Is It Still a Contraindication to Surgery? , 2008, Annals of surgery.

[27]  Yuman Fong,et al.  Actual 10-year survival after resection of colorectal liver metastases defines cure. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Donohue,et al.  Hepatic Resection for Colorectal Metastases: Value for Risk Scoring Systems? , 2007, Annals of surgery.

[29]  Evelyne M. Loyer,et al.  Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases , 2005, Annals of surgery.

[30]  Glatstein,et al.  "Just Another Statistic" , 1998, The oncologist.

[31]  A. Feinstein,et al.  Indexes and boundaries for "quantitative significance" in statistical decisions. , 1990, Journal of clinical epidemiology.

[32]  M. Nichelatti,et al.  Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta‐Analysis , 2017, Clinical colorectal cancer.

[33]  Daniel J Sargent,et al.  Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  K. Shannon,et al.  Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  G. Elisabeta Marai,et al.  Conditional Survival Analysis of Patients With Locally Advanced Laryngeal Cancer: Construction of a Dynamic Risk Model and Clinical Nomogram , 2017, Scientific Reports.

[36]  J. Choi,et al.  Dynamic prognostication using conditional survival analysis for patients with operable lung adenocarcinoma , 2016, Oncotarget.

[37]  Yuhree Kim,et al.  Curative Surgical Resection of Adrenocortical Carcinoma: Determining Long-term Outcome Based on Conditional Disease-free Probability , 2017, Annals of surgery.

[38]  M. Gönen,et al.  Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection. , 2017, Annals of surgery.

[39]  T. Pawlik,et al.  Pre-hepatectomy carcinoembryonic antigen (CEA) levels among patients undergoing resection of colorectal liver metastases: do CEA levels still have prognostic implications? , 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[40]  T. Pawlik,et al.  From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis. , 2016, Surgical oncology.

[41]  Yuhree Kim,et al.  Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases , 2016, Cancer.

[42]  T. Pawlik,et al.  Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases. , 2016, Anticancer research.

[43]  Yuhree Kim,et al.  Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases , 2016, Journal of Gastrointestinal Surgery.

[44]  Yuhree Kim,et al.  Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. , 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[45]  P. Lønning,et al.  Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases , 2016, International journal of cancer.

[46]  A. Russo,et al.  Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. , 2016, Critical reviews in oncology/hematology.

[47]  J. Saric,et al.  Significance of R1 Resection for Advanced Colorectal Liver Metastases in the Era of Modern Effective Chemotherapy , 2016, World Journal of Surgery.

[48]  T. Pawlik,et al.  Clinical and morphometric parameters of frailty for prediction of mortality following hepatopancreaticobiliary surgery in the elderly , 2016, The British journal of surgery.

[49]  J. Vauthey,et al.  RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases , 2016, Journal of Gastrointestinal Surgery.

[50]  G. Torzilli,et al.  Is Tumor Detachment from Vascular Structures Equivalent to R0 Resection in Surgery for Colorectal Liver Metastases? An Observational Cohort , 2016, Annals of Surgical Oncology.

[51]  M. Barone,et al.  Conditional survival analysis of hepatocellular carcinoma patients treated with radiofrequency ablation , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[52]  William R Jarnagin,et al.  Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? , 2015, Annals of surgery.

[53]  M. Choti,et al.  Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. , 2015, JAMA surgery.

[54]  M. Choti,et al.  Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases , 2015, Annals of Surgical Oncology.

[55]  A. Ejaz,et al.  Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 535 Patients. , 2015, JAMA surgery.

[56]  Yuhree Kim,et al.  Conditional disease-free survival after surgical resection of gastrointestinal stromal tumors: a multi-institutional analysis of 502 patients. , 2015, JAMA surgery.

[57]  J. Weissfeld,et al.  Prognosis and conditional disease-free survival among patients with ovarian cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  E. Oikonomou,et al.  BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications , 2014, Oncotarget.

[59]  J. Hodson,et al.  Performance of prognostic scores in predicting long‐term outcome following resection of colorectal liver metastases , 2014, The British journal of surgery.

[60]  Katherine S Panageas,et al.  Dynamic prognostication using conditional survival estimates , 2013, Cancer.

[61]  Steven A. Curley,et al.  RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases , 2013, Annals of surgery.

[62]  P. Balladur,et al.  Prognostic Impact of Positive Surgical Margins After Resection of Colorectal Cancer Liver Metastases: Reappraisal in the Era of Modern Chemotherapy , 2013, World Journal of Surgery.

[63]  R. Charnley,et al.  Prognostic Factors and Survival after Resection of Colorectal Liver Metastasis in the Era of Preoperative Chemotherapy: An 11-Year Single-Centre Study , 2013, Digestive Surgery.

[64]  J. Shindoh,et al.  Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases , 2012, Annals of surgery.

[65]  L. Bolondi,et al.  Conditional Survival after Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients , 2012, Clinical Cancer Research.

[66]  M. Choti,et al.  Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent , 2012, Cancer.

[67]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Greg Yothers,et al.  Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Hermann Brenner,et al.  Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J. Meyerhardt,et al.  Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.

[71]  R. Adam,et al.  R1 Resection by Necessity for Colorectal Liver Metastases: Is It Still a Contraindication to Surgery? , 2008, Annals of surgery.

[72]  Yuman Fong,et al.  Actual 10-year survival after resection of colorectal liver metastases defines cure. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  J. Donohue,et al.  Hepatic Resection for Colorectal Metastases: Value for Risk Scoring Systems? , 2007, Annals of surgery.

[74]  Evelyne M. Loyer,et al.  Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases , 2005, Annals of surgery.

[75]  Glatstein,et al.  "Just Another Statistic" , 1998, The oncologist.

[76]  A. Feinstein,et al.  Indexes and boundaries for "quantitative significance" in statistical decisions. , 1990, Journal of clinical epidemiology.